May was a ‘particularly deadly' month for suspected opioid overdoses in N.H.
Medics from AMR responded to 43 suspected opioid overdoses in Nashua and Manchester in May. But Stawasz said because Narcan is now widely available for free, it's likely there are many overdoses that continue to occur without 9-1-1 intervention.
Get N.H. Morning Report
A weekday newsletter delivering the N.H. news you need to know right to your inbox.
Enter Email
Sign Up
The increase in suspected opioid overdose deaths come after months of positive indicators, with overdoses trending down in recent months compared to last year in both cities.
Advertisement
But Stawasz said those improvements 'by no means signal that the opioid epidemic is 'under control' or close to elimination.'
'It is always possible that the trend of lower numbers could change quickly — as evidenced this month,' he said.
New Hampshire isn't the only state to see the sudden increase in deaths in May. Stawasz said Connecticut also saw a surge in both fatal and non-fatal overdoses around the state, with 61 suspected fatal overdoses between May 16 and June 6.
Advertisement
A bulletin from the
'That CT surge seems to correlate to the surge in deaths we experienced here in Nashua & Manchester,' Stawasz said in an email. 'The bulletin suggests that polysubstance combinations and higher concentrations of fentanyl may be contributing factors to the current spike in overdose deaths.'
While overdose deaths in Manchester are trending about 13 percent less than last year, in Nashua, they're up nearly 70 percent this year, according to AMR. There were 20 opioid deaths in 2024, and there's already been 14 so far this year in Nashua.
Meanwhile, in Manchester, the percentage of overdoses that were fatal shot up to 26 percent in May, more than double the rolling 12-month average of 11 percent.
Amanda Gokee can be reached at
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
R.I. overdose deaths decline for second year in a row
Publicly-accessible Boxes containing Naloxone, an opioid reversal drug also known by the brand name Narcan, line up outside the East Bay Recovery Center in Warren. (Photo by Alexander Castro/Rhode Island Current) Rhode Island saw its lowest number of fatal drug overdoses since 2020, according to health department data presented to the Governor's Overdose Task Force on Wednesday. 'This is a sign of hope,' Gov. Dan McKee said in a statement Wednesday. 'We know there is still much work ahead, but the steps we are taking are saving lives.' This is the second year in a row that overdose deaths have dropped. There were 329 Rhode Islanders who died from overdoses in 2024, representing an 18.6% decrease from 2023, and a 25% drop compared to 2022. That means the state is well on its way to achieving its goal of a 30% reduction for 2030. The goal was set in 2022, the year a total of 436 people died of drug overdoses. The 2024 data demonstrated another longstanding trend now broken: For the first time since 2013, cocaine-related deaths were implicated in 61% of fatal overdoses, surpassing the 57% of deaths associated with fentanyl. All opioid-related overdoses, in fact, fell from 85% the previous year to 69% in 2024. But more than one substance can contribute to an overdose, so distinguishing the role of cocaine or fentanyl in a death is not so neatly accomplished. A large portion of overdoses — 118 in all — involved both substances being used in tandem in 2024. About three in five people who died from cocaine also had fentanyl in their system. The annual overdose data is compiled and interpreted by the Rhode Island Department of Health's (RIDOH) Substance Use Epidemiology Program, which finished reviewing the 2024 results last week, according to Joseph Wendelken, a department spokesperson. The data is largely based on autopsy and toxicology findings from the Office of the State Medical Examiners. Personal medical history also informs the coroners' findings. The data does not include deaths with undetermined causes. 'Though decline is encouraging, this is still an incredible loss in our community,' Heidi Weidele, the health department's lead fatal overdose epidemiologist, told the task force Wednesday during her presentation on the data. The scale of loss did not affect all people equally: 70% of overdose deaths in 2024 were men, a number consistent with recent years. Similarly, people ages 45 to 54 were the largest age-based cohort of overdose deaths, followed by people ages 55 to 64. By race, non-Hispanic white Rhode Islanders comprised the largest share of overdoses at 73%, even though they were also most likely to have a history of substance use treatment. Most of the state's overdoses were concentrated in urban areas, with Woonsocket, Providence and Pawtucket reporting the highest numbers. Though decline is encouraging, this is still an incredible loss in our community. – Heidi Weidele, lead fatal overdose epidemiologist, Rhode Island Department of Health Weidele said the deceased most commonly worked in 'natural resources, construction, maintenance, and service occupations, which is similar to what we've seen in past years,' she told the task force. 'And service occupations would be things like health care support, law enforcement, food preparation, grounds maintenance, and personal care.' Other statistics from the report painted a grim picture of the deceased leading up to final moments: Most never sought substance use treatment, or received medical treatment for a previous overdose. Eight out of 10 died in private, in a home, garage or camper. Most overdosed alone, with no bystander present in 60% of cases. The availability of lethal drugs has also influenced overdose trends over the years. In 2009, prescription drugs accounted for 62% of overdose deaths. By 2020, prescription drugs accounted for only 9% of fatal overdoses, while illicit drugs like fentanyl and cocaine comprised 72% of overdose deaths. In 2024, the state actually saw 34% of deaths attributed to combinations of illicit and prescription drugs combined — the highest percentage since at least 2009. A few uncommon culprits in overdose deaths were still marked as 'substances of concern' by the state health department. These included novel benzodiazepines, tranquilizers which belong to the much broader category of research chemicals — substances derived from or chemically very similar to legal and regulated drugs. In this case, novel benzodiazepines like clonazolam — about two-and-a-half-times stronger than Xanax — accounted for nine fatalities in 2024. Brown University researcher: Street drugs are getting more potent and more mysterious Xylazine, a veterinary anesthetic increasingly being used to cut street-sourced opioids, was another rogue substance that continued to impact overdose data in 2024. It was involved in 37% of opioid-related deaths. 'Every single overdose death is preventable,' Health Department Director Dr. Jerry Larkin said in a statement Wednesday. 'Recovery is within reach for every person living with the disease of addiction.' McKee strengthened the Overdose Task Force — a coalition of more than 150 members divvied up into nine workgroups — in 2022 via an executive order, hoping to ensure a sustained state response to the opioid overdose crisis. Among the initiatives it steers are determining how to dispense opioid settlement funds, naloxone distribution networks, peer outreach, and recovery support and public awareness campaigns. Earlier this year, Rhode Island also opened the nation's first state-regulated harm reduction site at Project Weber/RENEW in south Providence, where people can use drugs and receive medical attention in the event of an overdose. Despite a fierce floor debate in the Rhode Island House of Representatives, legislation to extend the injection site's pilot authorization was extended by the General Assembly and later signed into law by McKee on June 6. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Yahoo
6 hours ago
- Yahoo
Douglas County health officials working to make resources accessible after surge in opioid overdoses
DCCCA offers naloxone through a vending machine outside of a Lawrence Transit station near the University of Kansas campus. (Maya Smith for Kansas Reflector) LAWRENCE — Public health officials are responding to a spike in opioid overdoses in Douglas County by offering free, lifesaving drugs, including through a vending machine. Lawrence-Douglas County Public Health called attention to overdose statistics in a social media post, stating the Kansas Department of Health and Environment identified 33 opioid overdoses between March and May in eastern Kansas. Douglas County accounted for a majority of emergency department visits in the area, double what would be expected in a two-month timeframe. 'This isn't just a Douglas County issue. This is a nationwide issue that unfortunately claims people's lives every year,' said Cara Hansuld, prevention services program manager at DCCCA, which provides community and social services. 'It's hard to say what the long-term effects are right now and if this is going to continue.' Douglas County resources DCCCA: Free Narcan and fentanyl test strips, and naloxone vending machine. Contact: info@ Lawrence-Douglas County Public Health: Free Narcan and test strips, no appointment needed. Contact: 785-843-3060. Treatment and Recovery Center: Open 24/7 for detox, mental health and substance use care. Contact: 785-843-9192. Heartland Community Health Center: Medication-assisted treatment, mental health care, walk-ins welcome. Contact: 785-841-7297. While public health officials have been swift to make lifesaving drugs like naloxone accessible to the public, other local experts are emphasizing the need for awareness and education. 'It's important for our residents to know what's happening,' Hansuld said. 'This indicates to me that there is more concentrated fentanyl or just a more dangerous strain of the substance that they're seeking. It's good for everyone to know so they can be prepared in case that happens to them or somebody close to them.' DCCCA has funded a naloxone vending machine outside of a Lawrence Transit station near the University of Kansas campus since Feb. 2024, providing free nasal spray when residents enter their zip code. Douglas County residents also can request free naloxone and fentanyl test strips online through DCCCA's website. 'This is a communitywide and national challenge that demands a coordinated, multifaceted response,' said Ryan Sztorch, senior director of crisis services at Bert Nash Community Mental Health Center in Lawrence. 'Reducing stigma is a key part of that process.' Lawrence-Douglas County Public Health provides naloxone and fentanyl test strips as well as education on how to use them. Executive director Jonathan Smith said it's crucial to share accurate, timely information about the clinic's resources to save lives. 'This is a moment for the community to be alert and educated about resources available to prevent overdoses from happening,' Smith said. 'The most important thing we can do is act early, raise awareness, and make sure people know where to go for support.' Organizations are working to spread awareness about the rise in overdoses across the county. For Douglas County, collaboration has been key in helping address the opioid crisis. 'Our community is fortunate to have a wide range of strengths and resources, and it's only through collective action that we can make meaningful progress,' Sztorch said. 'Each of these partners brings unique strengths — whether it's providing treatment, coordinating care, distributing Narcan, or offering lifesaving interventions. This united front is a testament to the power of community and shared purpose.' Bert Nash partners with first responders across the county to provide not only treatment but also mental health resources. Sztorch says that reducing the stigma of substance use means recognizing substance use disorders the same way we would other medical conditions, as well as their connection to mental health. 'Normalizing substance use disorders as medical conditions — just like diabetes or heart disease — is essential to saving lives,' said Sztorch. 'We also need insurance providers to recognize and support treatment for substance use disorders on par with other health conditions. We know that mental health and substance use are deeply interconnected — addressing one often supports healing in the other.' Although experts haven't identified a root cause to the uptick in overdoses, they agree the goal is to continue educating Douglas County residents and providing resources to those in need. 'Our focus right now is on preventing further harm,' Smith said. 'The resources are here, and we want to make sure our community knows how to access them.'
Yahoo
15 hours ago
- Yahoo
Antimicrobial Resistance Diagnostic Markets, Strategies and Trends Report 2025: Antimicrobial Resistance Spurs Innovation in Diagnostics and Opens Key Market Opportunities Across High-Burden Pathogens
Diagnostics drive progress against antimicrobial resistance by developing new technologies to diagnose pathogens and infections. Discover insights into the 6 Key Large Pathogen Opportunities, market forecasts, and profiles of over 30 companies leading the charge. Stay informed on this critical issue. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Antimicrobial Resistance Diagnostic Markets, Strategies and Trends by Pathogen and Technology, With Executive Guides and Customization" has been added to offering. As antimicrobial resistance (AMR) continues to pose a significant threat to global health, innovative diagnostic technologies are taking center stage in the effort to mitigate this challenge. These advancements could potentially address the resistance dilemma even in the face of delayed development of new antibiotics. Cutting-edge diagnostic tools, surpassing traditional gene sequencing methods, are being researched and developed to seize the expanding market opportunities within this vital healthcare domain. In an extensive analysis, the publisher sheds light on the technological landscape, covering a variety of sophisticated approaches for diagnosing pathogens and infections. We have pinpointed six major pathogen-related opportunities, underscoring their importance in the diagnosis and treatment of infectious diseases. Furthermore, we offer detailed market forecasts to aid stakeholders in navigating this rapidly evolving field. The study profiles over 30 leading companies, from industry giants to emerging innovators, all dedicated to advancing diagnostic solutions in the face of AMR. These entities are leveraging new technologies to enhance the accuracy, efficiency, and speed of pathogen detection, which is crucial in managing infections and curbing the spread of resistance. With AMR limiting the efficacy of current antibiotics, the role of diagnostics becomes even more critical. Enhanced diagnostic tools not only aid in identifying appropriate treatments faster but also enable more precise use of antibiotics, thereby contributing to the global effort to fight resistance. Current and future diagnostic technologies promise healthcare professionals more robust options in the ongoing battle against AMR. By expanding the avenues for early detection and precise pathogen identification, these technologies are essential in managing infectious disease threats and influencing treatment outcomes. As the world continues to grapple with AMR and its implications on public health, the development and implementation of advanced diagnostic solutions stand as a beacon of hope. The strategic insights and comprehensive market forecasts provided in the publisher's study serve as valuable resources for stakeholders aiming to capitalize on the innovations reshaping the fight against infectious diseases. Key Topics Covered: 1 Market Guides 1.1 Antimicrobial Resistance - Strategic Situation Analysis1.2 Guide for Executives and Business Development Staff1.3 Guide for Management Consultants and Investment Advisors 2 Introduction and Market Definition2.1 The Threat and Opportunity of Antimicrobial Resistance2.2 Defining the Opportunity2.2.1 Revenue Market Size 2.3 Methods and Sources 2.3.1 Methodology2.3.2 Sources2.3.3 Authors 2.4 Perspective: Healthcare and the IVD Industry2.4.1 Global Healthcare Spending 2.5 Spending on Diagnostics2.5.1 Important Role of Insurance for Diagnostics 3 Overview of a Dynamic Market 3.1 Players in a Dynamic Market 3.1.1 Diagnostic Test Developer3.1.2 Instrumentation Supplier3.1.3 Chemical/Reagent Supplier 3.1.4 Pathology Supplier 3.1.5 Independent Clinical Laboratory3.1.6 Public National/regional Laboratory 3.1.7 Hospital Laboratory3.1.8 Physicians Office Lab (POLS)3.1.9 Audit Body 3.1.10 Certification Body 3.2 Understanding Antimicrobial Resistance 3.2.1 What is Antimicrobial Resistance (AMR) 3.2.2 Bacteria and Other Microbes 3.2.3 The History of Antibiotics3.2.4 The Role of Animal Husbandry3.2.5 The Implications of Horizontal Transfer 3.2.6 The Threat of AMR3.3 The Changing Road to New Antibiotics & Technologies 3.4 The Key Role of Diagnostics in AMR 4 The Market Opportunity of AMR 4.1 The Key Large Market Opportunities in AMR 4.1.1 Streptococcus Pneumoniae (DRSP)4.1.2 Campylobacter (DRC)4.1.3 Clostridium Difficile (CD)4.1.4 Staphylococcus aureus (MRSA) 4.1.5 Neisseria gonorrhoeae (DRNG)4.1.6 Salmonella (DRNTS)4.2 Diagnostic Technology Development Opportunities 4.2.1 What's Wrong with Microbiology 4.2.2 The Features Battleground of Infectious Disease Diagnostics4.2.3 Multiplex vs. POC/Rapid4.2.4 The Miracle of Genetics4.2.5 From Multiple Pathogens to All Pathogens - The Next Next Generation4.2.6 Gene Sequence Diagnostics WITHOUT the Sequencing. 4.2.7 Markers of Resistance. 4.2.8 What Happens to the Microbiology Lab? 5 Antibiotic Resistance Diagnostics Recent Developments5.1 Antibiotic Resistance Recent Developments5.1.1 Importance of These Developments 5.1.2 How to Use This Section 5.2 FDA Clears New bioMerieux Diagnostic System and Panel5.3 Selux Diagnostics Phenotyping System Gets FDA Approval5.4 New diagnostics to tackle drug resistant infections 5.5 Takara Bio USA, Inc. and BioExcel Diagnostics Partner for Infectious Disease Panels 5.6 Three companies join forces to tackle antimicrobial resistance (AMR)5.7 T2 Biosystems Exercises BARDA Option 5.8 OpGen to Ramp up Use of Acuitas AMR Gene Panel 5.9 BD Partners With Pfizer, Wellcome to Study AMR Dx 5.10 Sepsis Test Developers Accelerate Plans 5.11 OpGen Receives FDA Clearance for AMR Panel 5.12 Visby Medical - Rapid Uptake of Handheld PCR Test for STIs5.13 MicroGenDx, OrthoKey Clinic and OrthoKey Surgery5.14 BioMerieux Receives CE Mark for Vitek Clinical Microbiology System 5.15 Hologic to Acquire Mobidiag5.16 Campylobacter strains exchange genes5.17 Disinfection spreads antimicrobial resistance 5.18 Molzym, Fraunhofer Developing Rapid Sepsis Dx 5.19 Illumina, IDbyDNA Build NGS-Based Respiratory Panel5.20 Accelerate Diagnostics Expands AMR Testing5.21 Rapid diagnostics linked to optimal antibiotics5.22 Visby Medical Wins AMR Diagnostic Competition 5.23 DNAe Technology SARS-CoV-2 Sequences 5.24 Infections with foodborne bacteria becoming harder to treat5.25 Dust is sharing antibiotic resistance genes 6 Key AMR Diagnostics Companies6.1 1928 Diagnostics6.2 Abacus Diagnostica 6.3 Abbott Laboratories6.4 Accelerate Diagnostics6.5 ADT Biotech6.6 Beckman Coulter Diagnostics 6.7 Becton, Dickinson and Company 6.8 Binx Health6.9 bioMerieux Diagnostics 6.10 Bio-Rad Laboratories, Inc.6.11 Cepheid (Danaher)6.12 Curetis N.V. / Curetis GmbH 6.13 Day Zero Diagnostics. 6.14 Enzo Biochem 6.15 Eurofins Scientific 6.16 Fusion Genomics.6.17 GeneFluidics 6.18 Genetic Signatures6.19 Great Basin Corporation6.20 Hologic6.21 Hutman Diagnostics6.22 Inflammatix 6.23 Linear Diagnostics.6.24 Lumos Diagnostics 6.25 Millipore Sigma 6.26 OpGen6.27 Ortho Clinical Diagnostics6.28 Perkin Elmer6.29 Qiagen6.30 Roche Molecular Diagnostics6.31 SeLux Diagnostics6.32 Sense Biodetection 6.33 Siemens Healthineers6.34 Sysmex 6.35 Thermo Fisher Scientific Inc. 6.36 Visby Medical 7 The Global Market for Antimicrobial Resistance Diagnostics 7.1 Global Market Overview by Country7.2 Global Market by Technology - Overview7.3 Global Market by Technology - Overview 8 Global Antibiotic Resistance Diagnostic Markets - By Pathogen8.1 Drug Resistant Streptococcus Pneumoniae - DRSP8.2 Drug Resistant Campylobacter - DRC8.3 Clostridium Difficile - CD8.4 Methicillin Resistant Staphylococcus Aureus - MRSA8.5 Drug Resistant Neisseria Gonorrhoeae - DRNG8.6 Drug Resistant Salmonella - DRNTS 9 Global Antibiotic Resistance Diagnostic Markets - by Technology9.1 Microbiology Culture9.2 Immunoassay9.3 PCR9.4 NGS9.5 Mass Spectrometry - MS9.6 Rapid and Point of Care - Rapid/POC 10 Vision of the Future of AMR Diagnostics 11 Appendices 11.1 United States Medicare System: Clinical Laboratory Fees Schedule For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
